Shilpa Sambashivan, Nura Bio CEO
June 22, 2026 06:00 AM EDT
FinancingStartups
Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration
Ayisha Sharma
Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration
Nura Bio raises $73.8M Series B to advance oral SARM1 inhibitors NB-4746 in ALS and NB-9402 through early clinical trials.
TL;DRAI
Nura Bio secures $73.8M Series B to advance SARM1 inhibitors for neurodegeneration, backed by Forbion, RA, and Sanofi Ventures. The round signals momentum in computational biotech where AI-driven drug discovery is now critical for pharma partnerships and M&A exit valuations.
153 words~1 min read
